Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients

Malmberg, Henrik; Grahne, Bertel; Holopainen, Elina; Binder, E.

doi:10.1111/j.1365-2273.1983.tb01441.x

Cited by 57 publications

(24 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although other more minor forms of rhinitis (e.g. occupational rhinitis, nonallergic hormonal rhinitis, food-induced rhinitis, emotioninduced rhinitis, physical/chemical irritant-induced rhinitis, and rhinitis of the elderly) (2)(3)(4)(5) have also been defined on the basis of limited information on aetiological and pathological factors, only drug-induced rhinitis, NARES, and idiopathic rhinitis will be discussed in greater detail to illustrate the general mechanisms that may be important in NANIPER.…”

Section: Introductionmentioning

confidence: 99%

Mechanisms of vasomotor rhinitis

Rp¹

2004

Allergy

View full text Add to dashboard Cite

Nonallergic non-infectious perennial rhinitis (NANIPER) is a heterogeneous disorder comprising several pathophysiological entities. The etiology of some of these disorders (e.g. drug-induced rhinitis, nonallergic rhinitis with eosinophilia syndrome [NARES], occupational rhinitis, hormonal rhinitis, emotion-induced rhinitis, physical/chemical irritant-induced rhinitis) is well established. In contrast, the aetiology of idiopathic forms of rhinitis (also known as vasomotor rhinitis) is largely unknown. Mechanistic studies have suggested that non-IgE-mediated inflammatory and/or neurogenic processes may be involved. There is evidence that localized inflammation is the underlying cause of symptoms in drug-induced rhinitis and NARES, since eosinophilia is an important pathophysiological component in these conditions. In contrast, neurogenic reflex mechanisms initiated by environmental factors appear to be involved in idiopathic rhinitis. It has been suggested that there may be an imbalance of the sympathetic and parasympathetic nervous systems, with parasympathetic hyper-activity and sympathetic hypo-activity resulting in nasal congestion and rhinorrhoea. Indirect evidence suggests that C-fibres may also play an important role in the pathophysiology of idiopathic rhinitis.

show abstract

Section: Introductionmentioning

confidence: 99%

Mechanisms of vasomotor rhinitis

Rp¹

2004

Allergy

View full text Add to dashboard Cite

show abstract

“…The same drug has also been used for treating patients with excess secretions as a component of non-allergic perennial rhinitis (25). The topical mode of administration was then used in the nose as well.…”

Section: Anticholinergicsmentioning

confidence: 99%

Pharmacological influence of antiallergic medication on in vivo allergen testing

Pipkorn

1988

Allergy

View full text Add to dashboard Cite

“…to q.i.d. administered for 3-4 weeks [6,8,[22][23][24][25][26][27][28][29][30]. However, a high incidence of nasal dryness.…”

Section: Discussionmentioning

confidence: 99%

Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life

Georgitis

Banov

Boggs

et al. 1994

Clin Experimental Allergy

View full text Add to dashboard Cite

Intranasal fluorocarbon anticholinergic agents have been used to treat the nasal hypersecretion of perennial non-allergic rhinitis, but chronic use has been restricted either due to the potential for systemic anticholinergic adverse events or due to the irritating properties of the fluorocarbon metered dose formulations. This study evaluates a new aqueous nasal formulation of ipratropium bromide (Atrovent Nasal Spray 0.03%) in subjects with perennial non-allergic rhinitis in a double-blind, placebo-controlled trial. Two hundred and twenty-eight patients were randomized to receive two sprays per nostril of either ipratropium bromide (42 micrograms/nostril) or placebo-administered three times a day as an aqueous nasal spray over an 8-week interval. Patients were evaluated bi-weekly and maintained daily diaries for duration and severity of nasal symptoms. Ipratropium bromide reduced the mean severity and duration of rhinorrhoea within the first week and throughout the 8 weeks of active treatment compared with placebo (P< 0.05). Secondary endpoints of efficacy (patient and physician global assessments and a quality of life assessment) also supported the use of ipratropium bromide nasal spray for rhinitis symptom control. With the reduction in rhinorrhoea by the ipratropium bromide nasal spray, patients reported a marked improvement in daily moods vs placebo (P < 0.01). Both placebo and ipratropium bromide nasal spray induced a modest reduction of nasal congestion, sneezing and postnasal drip. This improvement in these other nasal symptoms was consistent with the known soothing effects of a nasal saline vehicle. There were no drug-related serious or systemic anticholinergic adverse events.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients

Cited by 57 publications

References 2 publications

Mechanisms of vasomotor rhinitis

Mechanisms of vasomotor rhinitis

Pharmacological influence of antiallergic medication on in vivo allergen testing

Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life

Contact Info

Product

Resources

About